Important News & Announcements

Stay up to date with the latest news and announcements from NASCSA.

Back to all news

SAMHSA Harm Reduction Framework Draft Open for Public Comment

Posted 7/18/2023

Monday - July 16, 2023 - The Substance Abuse Mental Health Services Administration (SAMHSA)  announced that the agency's Harm Reduction Framework Draft is now open for public comment. The framework will inform SAMHSA's harm reduction activities, as well as related policies, programs, and practices.

SAMHSA's aims are to integrate harm reduction activities across its Centers and initiatives, and to do so in a manner that draws on evidence-based practices and principles while maintaining sustained dialogue with harm reductionists and people with lived and living experience. The framework will also inform SAMHSA of opportunities to work with other Federal, State, Tribal and local partners.

Comments on the Harm Reduction Framework Draft will be accepted now through 5 p.m. ET on August 14, 2023 and can be found here.

Back to all news

Sponsor Spotlight

COMPASS Pathways

COMPASS Pathways is delighted to be a sponsor of NASCSA and looks forward to both engaging with controlled substances authorities, NASCSA leadership, and members to learn about their important work, and educate about our company's mission and the innovations underway using novel therapies.

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments.

We are developing innovative therapies and, when appropriate, combining them with psychological support and next-generation digital tools to forge new, sustainable mental health care pathways.

Our investigational COMP360 psilocybin therapy is currently undergoing phase 3 investigation in treatment-resistant depression. We are also assessing COMP360 in anorexia nervosa and post-traumatic stress disorder, across multiple clinical studies.

Learn more

All Sponsors